100%

Scanned image of the page. Keyboard directions: use + to zoom in, - to zoom out, arrow keys to pan inside the viewer.

Page Options

Download this Issue

Share

Something wrong?

Something wrong with this page? Report problem.

Rights / Permissions

This collection, digitized in collaboration with the Michigan Daily and the Board for Student Publications, contains materials that are protected by copyright law. Access to these materials is provided for non-profit educational and research purposes. If you use an item from this collection, it is your responsibility to consider the work's copyright status and obtain any required permission.

March 10, 1994 - Image 10

Resource type:
Text
Publication:
The Michigan Daily, 1994-03-10

Disclaimer: Computer generated plain text may have errors. Read more about this.

10 - The Michigan Daily - Thursday, March 10, 1994

Women's track aims for top four at NCAAs

By DOUG STEVENS
DAILY SPORTS WRITER
For the Michigan women's track
and field team, this season has been
one of making goals and then suc-
cessfully meeting them.
Its first and primary goal was to
win the Big Ten. The Wolverines
achieved that two weeks ago.
Then came Michigan's quest to
qualify a significant number of women
for the NCAA meet. It qualified ten
team members, one of the largest con-
tingents in the country.
~ This weekend, the team will strive
to meet a third goal: finishing in the
top four at the NCAA Champion-
ships.

U U

4&%k

215 S.

Tn"pAnn
( u p P

State St.
Arbor
DEAD
stairs)

-Aw"

Michigan, which is heading into
Indianapolis as the fourth seed, will
need to score 30 to 32 points to come
in fourth, according to assistant coach
Mike McGuire.
"People will have to come
through," McGuire said.
The Wolverines should be given a
significant challenge from LSU, the
two-time defending champions, as
well as Texas and Alabama.
Michigan should receive the bulk
of its scoring from the distance run-
ners. Molly McClimon, the winner of
both the 3000 meters and 5000 meters
at the Big Ten meet, is seeded second
in the 5000 meters at NCAAs. She
also is a member of the top-seeded
distance medley relay team,

Courtney Babcock, who was the
victor in the mile at the Big Ten meet,
will also be running the 5000 meters
and distance medley relay. She is the
third-seed in the 5000. Villanova's
Jennifer Rhines is the top-seed.
Both McClimon and Babcock also
qualified for the NCAAs in the 3000
meters and the mile.
"We are playing Russian Roulette
if we stretch kids too far at nationals,"
McGuire responded when being asked
about McClimon and Babcock not
running the mile or 3000.
"I am very happy with the events
that I'm running." McClimon said. "I
am just going to try to race as best as
possible,"
The Wolverines' distance med-
ley relay team is going into the
NCAA Championships with the fast-
est time in the country this season.
The team is comprised of Babcock,
McClimon, Richelle Webb and
Kristine Westerby.
Westerby will also be runningthe
800 meters, along with Jessica Kluge,
the Big Ten; champion in that event.
These two women are both poteitial
scorers for Michigan.
"I don't think Westerby andKluge
have peaked yet," McGuire said.
Other distance runners who will
compete this weekend include Chris
Szabo in the 3000 meters and Karen
Harvey in the mile.
In the high jump, Michigan will be

represented by Linda Stuck and Monika
Black, who finished second and third
respectively, at the Big Ten meet.
Tearza Johnson, who finished in
third place in the conference, will run

the 200 meters.
"As a team, we have to get out and
compete real hard, and let's see what
happens when the dust clears,"
McGuire said.

Darts + Dart Supplies \
Large selection
Free Flights w/ every Purchase of Darts

44

Graduation:

...*** M This is your moment
Ifyou have something to share
with classmates,family, andfriends:
Here is your opportunity
Wanted:
Student Speakers for the 1994
LS&A Spring Commencement
(Fourth annual competition)
Who: Open to all LS&A seniors eligible to graduate by
the end of Winter Term 1994.
What. Two students will each deliver a 2 minute
commencement speech at the LS&A Spring
Commencement on Saturday, April 30 at 12:00
noon in Michigan Stadium.
When: The deadline for entries is Friday, March 11 at
5:00 pm. All speeches will be judged by the
LS&A student commencement committee. Final
selections will be made by Monday, March 28.
Send typed texts to:
LS&A Development and External Relations
350 South Thayer, Ann Arbor, MI 48104-1608

a

Who ants,
. all
realy cool job
" Id " I o!
"Count me in!"
The Michigan Daily is hiring!

ted
LiWill
o sell
ary.
.

SPORTS INFORMATION
High jumper Monika Black will be one of the 10 members of the Michigan
women's track and field team to compete at this weekend's NCAA meet.

Department of Recreational
Sports
INTRAMURAL
SPORTS PROGRAM

WANTED!
Broomball Officials
Clinic Begins: Thursday 3/10
7:00 p.m.
IMSB
For Additional Information Contact IMSB 763-3562

The Display Department is looking for some highly
students to join our sales team. As an Account Execu
meet and communicate with Ann Arbor businesses it
advertisements. Sales experience is helpful, but no
Pick up an application at the Student PublicationsI
Applications due today

Y motival
tive, you
n order to
t necessa
Building.

420 Maynard

I

m mi

I 14 ~ID~i.L I :
Contraceptive Injection
(sterile medroxyprogesterone acetate suspension, USP)
WHAT IS DEPO-PROVERA CONTRACEPTIVE INJECTION?
DEPO-PROVERA Contraceptive Injection is a form of birth control that is given as an intra-
muscular injection (a shot) in the buttock or upper arm once every 3 months. To continue
your contraceptive protection, you must return for your next injection promptly at the end of
3 months. DEPO-PROVERA contains medroxyprogesterone acetate, a chemical similar to
(but not the same as) the natural hormone progesterone, which is produced by your ovaries
during the second half of your menstrual cycle. DEPO-PROVERA acts by preventing your
egg cells from ripening. If an egg is not released from the ovaries during your menstrual
cycle, it cannot become fertilized by sperm and result in pregnancy. DEPO-PROVERA also
causes changes in the lining of your uterus that make it less likely for pregnancy to occur.
HOW EFFECTIVE IS DEPO-PROVERA CONTRACEPTIVE INJECTION?
DEPO-PROVERA is over 99% effective, making it one of the most reliable methods of birth
control available. This means that the average annual pregnancy rate is less than one for
every 100 women who use DEPO-PROVERA. The effectiveness of most contraceptive
methods depends in part on how reliably each woman uses the method. The effectiveness
of DEPO-PROVERA depends only on the patient returning every 3 months for her next
injection. Your health-care provider will help you compare DEPO-PROVERA with other con-
traceptive methods and give you the information you need in order to decide which contra-
ceptive method is the right choice for you.
The following table shows the percent of women who got pregnant while using different
kinds of contraceptive methods. It gives both the lowest expected rate of pregancy (the
rate expected in women who use each method exactly as it should be used) and the typical
rate of pregnancy (which includes women who became pregnant because they forgot to
use their birth control or because they did not follow the directions exactly).
PERCENT OF WOMEN EXPERIENCING AN ACCIDENTAL PREGNANCY
IN THE FIRST YEAR OF CONTINUOUS USE
Lowest
Method Expected Typical
DEPO-PROVERA 0.3 0.3
Implants (Norplant) 0.3 0.3
Female sterilization 0.2 0.4
Male sterilization 01 0.15
Oral contraceptive (pill) - 3
Combined 0.1-
Progestogen only 0.5 -
IUD- 3
Progestasert 2.0-
Copper T 380A 0.8-
Condom (without spermicide) 2 12
Diaphragm (with spermicide) 6 18
Cervical Cap 6 18
Withdrawal 4 18
Periodic abstinence 1 - 9 20
Spermicide alone 3 21
Vaginal Sponge
Used before childbirth 6 18
Used after childbirth 9 28
No method 85 85
Source: Trussell et al; Obstet Gyncol 76:558,1990
WHO SHOULD NOT USE DEPO-PROVERA CONTRACEPTIVE INJECTION?
Not all women should use DEPO-PROVERA. You should not use DEPO-PROVERA if you
think you might be pregnant, have any vaginal bleeding without a known reason, have
had cancer of the breast, have had a stroke, have or have had blood clots (phlebitis) in
your legs, have problems with your liver or liver disease, or are allergic to DEPO-
PROVEA (medroxyprogesterone acetate or any of its other ingredients). You will have a
physical examination before your doctor prescribes DEPO-PROVERA. It is important to
tell your doctor if you are taking any prescription or over-the-counter medications or if
you have a family history of breast cancer; an abnormal mammogram (breast x-ray)
fibrocystic breast disease, breast nodules or lumps, or bleeding from your npples; kidney
disease; irregular or scanty menstrual periods; high blood pressure; migraine headaches;
asthma; epilepsy (convulsions or seizures); diabetes or a family history of diabetes; or a
hstoryof dress~ion.

occur and, therefore, the bleeding that comes with your normal menstruation does not take
place. When you stop using DEPO-PROVERA your menstrual period will usually, in time,
return to its normal cycle.
2. Bone Mineral Changes
Use of DEPO-PROV ERA may be associated with a decrease in the amount of mineral
stored in your bones. This could increase your risk of developing bone fractures. The rate
of bone mineral loss is greatest in the early years of DEPO-PROVERA use, but after that, it
begins to resemble the normal rate of age-related bone mineral loss.
3. Cancer
Studies of women who have used different forms of contraception found that women who
used DEPO-PROVERA for contraception had no increased overall risk of developing cancer
of the breast, ovary, uterus, cervix, or liver. However, women under 35 years of age whose
first exposure to DEPO-PROVERA was within the previous 4 years may have a slightly
increased risk of developing breast cancer similar to that seen with oral contraceptives.
You should discuss this with your health-care provider.
4. Accidental Pregnancy
Because DEPO-PRO VERA is such an effective contraceptive method, the risk of accidental
pregnancy for women who get their shots regularly (every 3 months) is very low. While there
have been reports of an increased risk of low birth weight and neonatal infant death or
other health problems in infants conceived close to the time of injection, such pregnancies
are rare. If you think you may have become pregnant while using DEPO-PROVERA for con-
traception, see your health-care provider as soon as possible.
5. Other Risks
Women who use hormone-based contraceptives may have an increased risk of blood clots
or stroke. Also, if a contraceptive method fails, there is a possibility that the fertilized egg
will begin to develop outside of the uterus (ectopic pregnancy). While these events are rare,
you should tell your health-care provider if you have any of the problems listed in the next
section.
WHAT SYMPTOMS MAY SIGNAL PROBLEMS WHILE USING DEPO-PROVERA
CONTRACEPTIVE INJECTION?
Call your health-care provider immediately if any of these problems occur following an
injection of DEPO-PROVERA: Sharp chest pain, coughing of blood, or sudden shortness of
breath (indicating a possible clot in the lung); sudden severe headache or vomiting, dizzi-
ness or fainting, problems with your eyesight or speech, weakness, or numbness in an arm
or leg (indicating a possible stroke); severe pain or swelling in the calf (indicating a possible
clot in the leg); unusually heavy vaginal bleeding; severe pain or tendemness in the lower
abdominal area; or persistent pain, pus, or bleeding at the injection site.m
WHAT ARE THE POSSIBLE SIDE EFFECTS OF DEPO-PROVERA
CONTRACEPTIVE INJECTION?
1. Weight Gain
You may experience a weight gain while you are using DEPO-PROVERA. About two thirds
of the women who used DEPO-PROVERA in clinical trials reported a weight gain of about 5
pounds during the first year of use. You may continue to gain weight after the first year.
Women in one large study who used DEPO-PROVERA for 2 years gained an average total
of 8.1 pounds over those 2 years, or approximately 4 pounds per year. Women who contin-
ued for 4 years gained an average total of 13.8 pounds over those 4 years, or approximate-
ly 3.5 pounds per year. Women who continued for 6 years gained an average total of 16.5
pounds over those 6 years, or approximately 2.75 pounds per year.
2. Other Side Effects
In a clinical study of over 3,900 women who used DEPO-PROVERA for up to 7 years, some
women reported the following effects that may or may not have been related to their use of
DEPO-PROVERA: Irregular menstrual bleeding, amenorrhea, headache, nervousness,
abdominal cramps, dizziness, weakness or fatigue, decreased sexual desire, leg cramps,
nausea, vaginal discharge or irritation, breast swelling and tenderness, bloating, swelling of
the hands or feet, backache, depression, insomnia, acne, pelvic pain, no hair growth or
excessive hair loss, rash, and hot flashes. Other problems were reported by veryfew of the
women in the clinical trials, but some of these could be serious. These include convulsions,
jaundice, urinary tract infections, allergic reactions, fainting, paralysis, osteoporosis, lack of
return to fertility, deep vein thrombosis, pulmonary embolus, breast cancer, or cervical can-
cer. If these or any other problems occur during your use of DEPO-PROVERA, discuss
them with your health-care provider.
SHOULD ANY PRECAUTIONS BE FOLLOWED DURING USE OF DEPO-PROVERA
CONTRACEPTIVE INJECTION?
1. Missed Periods
During the time you are using DEPO-PROVERA for contraception, you may skip a period,
or your periods may stop completely. If you have been receiving your DEPO-PROVERA
injections regularly every 3 months, then you are probably not pregnant. However, if you
think that you may be pregnant, see your health-care provider.
2. Laboratory Test Interactions
f you are scheduled for any laboratory tests, tell your health-care provider that you are
using DEPO-PROVERA for contraception. Certain blood tests are affected by hormones
such as DEPO-PROVERA.
3. Drug Interactions
Cytadren (aminoglutethimide) is an anticancer drug that. may significantlyidecrease the
effecivenes of DEPO-PROVERA if the two drugs are given during the same'time.

Take the best
training program
In the business a n-
our MCAT Total Training includes dynamic class
sessions, four testing sessions, our five-volume
Home Study Notes, one-on-one unlimited
tutoring, extra help sessions, and the unique
resources of the Training Library, including
Kaplan and AAMC practice tests. When you
study with Kaplan, you get training and cross-

'

I

Back to Top

© 2020 Regents of the University of Michigan